ClinicalTrials.gg
Not yet recruitingNCT07819851ADDICT-IAUpdated Sep 15, 2026

A Study of the Correlation Between the Severity of Substance Use Disorder and the Intensity of Dependence on Generative Artificial Intelligence

An interventional study of Questionnaire assessment in Substance-related Disorders, Behavior, Addictive and Artificial Intelligence (AI), sponsored by Centre Hospitalier Universitaire de Nice. Not yet recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-15.

Sponsored by Centre Hospitalier Universitaire de Nice · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This bicentric, cross-sectional observational study conducted in France evaluates the relationship between substance use disorder (SUD) severity and generative artificial intelligence dependency among outpatients treated in specialized addiction care centers (CSAPA).

While conversational generative artificial intelligence tools have seen rapid widespread adoption, potential problematic usage and cognitive dependency remain poorly documented in clinical addictology. Outpatients followed for substance use disorders present shared cognitive, reward-processing, and behavioral vulnerabilities that may heighten their susceptibility to emerging digital dependencies.

Eligible adult patients complete a single 15-minute evaluation comprising the Generative Artificial Intelligence Dependency Scale (GAIDS; 11 items rated on a 5-point Likert scale from 1 to 5, total score range: 11 to 55) and the DSM-5 diagnostic criteria checklist for their primary substance of abuse, alongside sociodemographic characteristics. Clinical data, including documented psychiatric comorbidities, are extracted in parallel from electronic health records. Following questionnaire completion, participants receive a dedicated debriefing and clinical restitution interview with an investigator.

The primary objective is to evaluate the linear correlation between SUD severity (number of validated DSM-5 criteria, from 0 to 11) and generative artificial intelligence dependency intensity (total raw GAIDS score). Secondary objectives aim to describe generative artificial intelligence dependency levels across specific primary substance classes (alcohol, tobacco, cannabis, cocaine, opioids, etc.), documented comorbid psychiatric disorders (e.g., mood disorders, ADHD, anxiety, personality disorders), and sociodemographic subgroups (age brackets, sex, education, and occupational status).

02

Conditions studied

  • Substance-related Disorders
  • Behavior, Addictive
  • Artificial Intelligence (AI)

Keywords

  • Artificial Intelligence
  • Addictive behavior
  • Substance-related disorders
03

In context

Substance-Related Disorders

2,238 studies on the registry are indexed under Substance-Related Disorders; 409 are open to participants now.

This study's planned enrollment of 100 is close to the median of 108 across 1,840 interventional studies indexed under Substance-Related Disorders.

Browse Substance-Related Disorders studies →

Lead sponsor

Centre Hospitalier Universitaire de Nice is the lead sponsor of 723 studies on the registry; 176 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patient (aged 18 years or older), with or without legal protection measures
  • Actively followed for a substance use disorder (SUD) characterized according to criteria at a participating specialized addiction care center (Nice University Hospital or Sainte-Marie Hospital in Nice, France).
  • Self-reported use of a conversational generative artificial intelligence tool at least once in the past 12 months.
  • Ability to understand, read, and complete a self-administered questionnaire in French.
  • Oral non-opposition obtained from the patient (and from their legal representative if applicable).
  • Affiliated with or beneficiary of a French social security healthcare system.

Exclusion criteria

Exclusion Criteria:

  • Minor patient (\< 18 years old).
  • Major neurocognitive disorders, intellectual disability, or acute psychiatric decompensation precluding comprehension or questionnaire completion.
  • Explicit opposition to participate expressed by the patient or their legal representative.
  • Withdrawal of non-opposition during the study.
  • Incomplete questionnaire or clinical record preventing computation of primary scores.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    CSAPA outpatients using generative AI

    Other: Questionnaire assessment

Interventions

  • OtherQuestionnaire assessment

    Administration of a single cross-sectional self-questionnaire assessing generative AI dependency (11-item GAIDS scale), DSM-5 substance use disorder criteria (0 to 11 criteria), and sociodemographic data, followed by a personalized debriefing and clinical restitution interview with an investigator (total duration: approximately 15 minutes).

06

What researchers measure

Primary outcomes

  1. Correlation coefficient between substance use disorder severity and generative AI dependency

    Linear correlation coefficient (Pearson or Spearman, depending on distribution normality) between the number of validated DSM-5 criteria for the primary substance (score ranging from 0 to 11, higher scores indicate greater severity) and the total raw score on the Generative Artificial Intelligence Dependency Scale (GAIDS; 11 items rated on a 5-point Likert scale from 1 to 5; total score range: 11 to 55; higher scores suggest greater dependency).

    Time frame: Baseline (single cross-sectional assessment, Day 0)

Secondary outcomes

  1. Generative artificial intelligence dependency score broken down by primary substance

    Descriptive statistics (mean +/- standard deviation or median) of the total raw score on the Generative Artificial Intelligence Dependency Scale (GAIDS; 11 items rated on a 5-point Likert scale from 1 to 5; total score range: 11 to 55; higher scores suggest greater dependency) broken down by primary substance classes (alcohol, tobacco, cannabis, cocaine hydrochloride, crack cocaine, opioids, benzodiazepines, amphetamines, other substances).

    Time frame: Baseline (Day 0)

  2. Generative artificial intelligence dependency score broken down by psychiatric comorbidities

    Descriptive statistics (mean +/- standard deviation or median) of the total raw score on the Generative Artificial Intelligence Dependency Scale (GAIDS; 11 items rated on a 5-point Likert scale from 1 to 5; total score range: 11 to 55; higher scores suggest greater dependency) broken down by documented DSM-5 psychiatric comorbidities (unipolar depressive disorders, bipolar disorders, schizophrenia spectrum and other psychotic disorders, ADHD, ASD, anxiety disorders, OCD, PTSD, borderline personality disorder, antisocial personality disorder, eating disorders, other, or absence of disorder).

    Time frame: Baseline (Day 0)

  3. Generative artificial intelligence dependency score broken down by sociodemographic characteristics

    Descriptive statistics (mean +/- standard deviation or median) of the total raw score on the Generative Artificial Intelligence Dependency Scale (GAIDS; 11 items rated on a 5-point Likert scale from 1 to 5; total score range: 11 to 55; higher scores suggest greater dependency) broken down by sociodemographic characteristics: age brackets (18-24, 25-39, 40-59, 60+), sex, occupational status (employed, student/in training, unemployed), and highest educational level (less than high school, high school diploma, short higher education, long higher education).

    Time frame: Baseline (Day 0)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07819851
Responsible party
Sponsor
First posted
Sep 15, 2026
Start date
Oct 5, 2026 (estimated)
Primary completion
Jun 5, 2027 (estimated)
Completion
Jun 5, 2027 (estimated)
Last update
Sep 15, 2026

Study contacts

Bruno GIORDANA, Dr
Contact
giordana.b@chu-nice.fr
4 92 03 87 75 ext. +33

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion